Cargando…

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans

One fifth of the world population live in East Asia comprising Japan, Korea, and China where ischemic heart disease, a major component of atherosclerotic cardiovascular disease (ASCVD), is the second most frequent cause of death. Each of low-density lipoproteins (LDL), remnant lipoproteins, and lipo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doi, Takahito, Langsted, Anne, Nordestgaard, Børge G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627775/ https://www.ncbi.nlm.nih.gov/pubmed/37704428 http://dx.doi.org/10.5551/jat.RV22013

Ejemplares similares

ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk
por: Johannesen, Camilla D. L., et al.
Publicado: (2022)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study
por: Wadström, Benjamin N., et al.
Publicado: (2023)

Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study
por: Johannesen, Camilla Ditlev Lindhardt, et al.
Publicado: (2020)

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality
por: Kaltoft, Morten, et al.
Publicado: (2022)

Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
por: Lütjohann, Dieter, et al.
Publicado: (2023)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review
por: Bruckert, Eric, et al.
Publicado: (2020)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Low-density lipoprotein cholesterol and risk of COPD: Copenhagen General Population Study
por: Freyberg, Josefine, et al.
Publicado: (2023)

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
por: Ginsberg, Henry N, et al.
Publicado: (2021)

Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
por: Nordestgaard, Liv Tybjærg, et al.
Publicado: (2022)

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
por: Wilkinson, Michael J., et al.
Publicado: (2023)

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
por: Makris, Anastasios, et al.
Publicado: (2023)

Nutritional Therapy for Asian Patients at Risk for Atherosclerotic Cardiovascular Disease
por: Lim, Hyunjung, et al.
Publicado: (2019)

Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol
por: Roy, Satyajeet
Publicado: (2014)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
por: Fuior, Elena Valeria, et al.
Publicado: (2023)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
por: Tada, Hayato, et al.
Publicado: (2019)

Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low‐Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients
por: Okerson, Ted, et al.
Publicado: (2017)

HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
por: Kjeldsen, Emilie W., et al.
Publicado: (2021)

The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting
por: Tani, Shigemasa
Publicado: (2020)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem
por: Gidding, Samuel S., et al.
Publicado: (2019)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

Age‐Related Associations of Low‐Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population‐Based Cohort Study
por: Jung, Han Na, et al.
Publicado: (2022)

Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy
por: Chiang, John Y. L., et al.
Publicado: (2020)

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
por: Ference, Brian A., et al.
Publicado: (2017)

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
por: Kapur, Navin K, et al.
Publicado: (2008)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

The Burden of Atherosclerotic Cardiovascular Disease in South Asians Residing in Canada: A Reflection From the South Asian Heart Alliance
por: Bainey, Kevin R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ogsogai7d61vav75126sem25rv